SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-004061
Filing Date
2024-01-29
Accepted
2024-01-29 08:05:34
Documents
20
Period of Report
2024-01-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 70060
2 ex4-1.htm EX-4.1 128262
3 ex10-1.htm EX-10.1 38846
4 ex10-2.htm EX-10.2 93586
5 ex99-1.htm EX-99.1 21604
6 ex99-2.htm EX-99.2 11342
  Complete submission text file 0001493152-24-004061.txt   651639

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE cing-20240125.xsd EX-101.SCH 3781
8 XBRL DEFINITION FILE cing-20240125_def.xml EX-101.DEF 26635
9 XBRL LABEL FILE cing-20240125_lab.xml EX-101.LAB 36718
10 XBRL PRESENTATION FILE cing-20240125_pre.xml EX-101.PRE 25259
21 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5635
Mailing Address 1901 W. 47TH PLACE KANSAS CITY KS 66205
Business Address 1901 W. 47TH PLACE KANSAS CITY KS 66205 (913) 942-2300
Cingulate Inc. (Filer) CIK: 0001862150 (see all company filings)

IRS No.: 863825535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40874 | Film No.: 24570149
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)